Skip to main content
Log in

Molekularpathologische Analyse des KRAS-Mutationsstatus beim metastasierten kolorektalen Karzinom

Ein erster Ansatz prädiktiver Pathologie

Molecular pathology analysis of the KRAS mutation status in patients with metastasized colorectal carcinoma

An initial approach using predictive pathology

  • Pathologie-Forum
  • Published:
Der Pathologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1

Literatur

  1. Van Cutsem E, Peeters M, Siena S et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658–1664

    Article  Google Scholar 

  2. Amado RG et al. Eur J Cancer 5(4–6) 7 LB, Abstract 0007

  3. De Roock W, Piessevaux H, De Schutter J (2007) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol (Epub ahead of print)

  4. Freeman et al. Eur J Cancer 5(4–6) 7 LB, Abstract 3014

  5. Tabernero J (2007) The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5: 203–220

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Keine Angaben.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A. Tannapfel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tannapfel, A. Molekularpathologische Analyse des KRAS-Mutationsstatus beim metastasierten kolorektalen Karzinom. Pathologe 29, 93–96 (2008). https://doi.org/10.1007/s00292-007-0966-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00292-007-0966-y

Navigation